Group 1 - Zhaoyi Innovation plans to issue H-shares and list on the Hong Kong Stock Exchange, considering the interests of existing shareholders and market conditions [3] - ST Zhongdi has decided to abandon the commercial opportunity for the Jiageng Ke Yi City land project, with the controlling shareholder planning to develop the project instead [4] - Xichang Electric Power expects a reduction of approximately 5.4 million yuan in net profit for 2025 due to adjustments in the time-of-use electricity pricing mechanism [5] Group 2 - Sanfu New Materials intends to invest 620 million yuan in a project for high-safety dry electrode battery key materials and high-frequency electronic information composite materials [6] - Weifu High-Tech's subsidiary plans to establish a joint venture with Baolong Technology to expand the active suspension motor hydraulic pump business [7] - Yulong Co., Ltd. will have its stock delisted on May 27, 2025, following a decision by the Shanghai Stock Exchange [8] Group 3 - Chen'an Technology's shareholder is transferring 6.27% of the company's shares to Hefei Guotou, aiming to introduce strategic investors [9] - Huamao Technology is planning to acquire a 100% stake in Fuchuang Youyue, with stock trading suspended for up to 10 trading days [11] - Baolong Technology's subsidiary will collaborate with Weifu High-Tech's subsidiary to develop core components for the active suspension system [12] Group 4 - Zhongnong Lihua intends to acquire at least 50% of Taizhou Agricultural Supplies, enhancing its product and service range [13] - Weiling Co., Ltd.'s subsidiary has successfully acquired 74.3% of Jiayu Mining for 220 million yuan, focusing on expanding into the non-ferrous metal resource sector [14][15] - Hengshi Technology's subsidiary has been approved for public transfer of shares on the New Third Board [16] Group 5 - Xiang Teng New Materials plans to acquire an additional 12.5% stake in its subsidiary Shanghai Shangda for 25.3 million yuan [17] - ST Texin has extended its employee stock ownership plan by 12 months, reflecting confidence in the company's long-term development [18] - Baili Electric has issued a risk warning regarding its stock price increase, indicating no significant changes in fundamentals [19] Group 6 - Hu Silicon Industry plans to acquire minority stakes in three semiconductor companies for approximately 7.04 billion yuan [20][21] - Demais plans to change its controlling shareholder, leading to a temporary suspension of stock trading [22] - FAW Fuwei has received a notice from a well-known new energy brand for a project expected to generate 1.06 billion yuan in total sales over its lifecycle [23] Group 7 - Hangyang Co. plans to establish a subsidiary for a large modular cryogenic equipment manufacturing project with an estimated investment of 557 million yuan [24] - Jiewate intends to acquire 40.89% of Tianyi Hexin for 319 million yuan, enhancing its product line in the signal chain category [25] - Dingxin Communications has elected a new chairman following the resignation of the previous chairman [26][27] Group 8 - Aofei Entertainment plans to invest 10 million yuan in a partnership to indirectly invest in AI robotics company Xuan Yuan Technology [28] - Huaxi Energy's controlling shareholder has been detained, but the company states that operations remain normal [29] - Yihe Jiaye will change its stock name to "Ruimaite" starting May 21 [30] Group 9 - Zhongjin Environment will change its name to "Southern Pump Industry" effective May 21 [31] - Hong Sifang's subsidiary plans to invest approximately 1.49 billion yuan in a new chemical materials and fertilizers industrial park [32] - Buchang Pharmaceutical's subsidiary has signed a research agreement for MF59 adjuvant with a pharmaceutical company [33] Group 10 - Hongjing Technology has signed a service contract worth 597 million yuan for a smart computing project [34] - Zhuojin Co. has won a bid for a soil remediation project worth 67.68 million yuan [35] - Xinjiang Jiaojian has been awarded a contract for a highway project valued at 451 million yuan [36] Group 11 - China National Materials Energy's subsidiary has signed a contract for an EPC project in Uzbekistan worth approximately 1.252 billion yuan [37] - Ruixin Microelectronics' shareholder plans to reduce its stake by up to 2% [38] - Shanghai Yizhong's shareholder also plans to reduce its stake by up to 2% [39] Group 12 - Sanyou Medical's controlling shareholder plans to reduce its stake by up to 1.44% [40] - Hangdian Co.'s controlling shareholder plans to reduce its stake by up to 1.93% [41] - Shangwei New Materials' shareholder plans to reduce its stake by up to 3% [42] Group 13 - Mingchen Health plans to repurchase shares worth between 30 million and 50 million yuan [43] - Jiuhua Tourism plans to raise up to 500 million yuan through a private placement for various projects [44] - Yuegui Co. plans to raise up to 900 million yuan for several projects [46]

受名称变更的影响，仍将按约定的内容履行。 北京怡和嘉业医疗科技股份有限公司董事会 证券代码：301367 证券简称：怡和嘉业 公告编号：2025-043 北京怡和嘉业医疗科技股份有限公司 关于变更公司名称、证券简称暨完成工商变更登记的公 告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 重要提示： 怡和嘉业医疗科技股份有限公司"变更为"北京瑞迈特医疗科技股份有限公司"。 日。 一、公司变更公司名称、证券简称的情况 公司名称、证券简称及修订 <公司章程> 的议案》，上述议案已经公司于 2025 年 5 月 13 日召开 2024 年年度股东大会审议通过，具体内容详见公司于 2025 年 4 月 18 日、2025 年 5 月 14 日于巨潮资讯网（http://www.cninfo.com.cn）披露的相关公告。 公司变更中文名称、证券简称，公司英文名称及证券代码保持不变。具体情况如下： 变更前 变更后 中文名称 北京怡和嘉业医疗科技股份有限公司 北京瑞迈特医疗科技股份有限公司 英文名称 BMC Medical Co., Ltd. BMC Medical Co ...

Core Viewpoint - The company has approved a profit distribution plan for the year 2024, which includes a cash dividend distribution to shareholders based on the adjusted total share capital after excluding repurchased shares [1][2][3]. Profit Distribution Plan - The total cash dividend to be distributed is RMB 35,548,928.00 (including tax) [1][2]. - The distribution is based on a total share capital of 89,600,000 shares, excluding 727,680 shares that do not participate in the profit distribution, resulting in a base of 88,872,320 shares for the calculation [1][2]. - Each shareholder will receive a cash dividend of RMB 4.00 per 10 shares (including tax) [2][3]. Taxation Details - For Hong Kong market investors and certain foreign institutions, the cash dividend after tax will be RMB 3.60 per 10 shares [2]. - A differentiated tax rate applies to individual shareholders based on their holding period, with specific tax amounts outlined for different durations [2]. Key Dates - The record date for shareholders to be eligible for the dividend is May 27, 2025 [3]. - The ex-dividend date is set for May 28, 2025 [3]. Distribution Method - The cash dividends will be directly credited to the shareholders' accounts through their securities companies or other custodians [3][4]. Adjustments and Compliance - The company will adjust the total distribution amount if there are changes in the total share capital before the record date, maintaining the distribution ratio [1][4]. - The company is responsible for any legal liabilities arising from insufficient cash dividends due to changes in shareholder accounts during the distribution application period [4].

证券代码：301367 证券简称：怡和嘉业 公告编号：2025-042 北京怡和嘉业医疗科技股份有限公司 2024年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、北京怡和嘉业医疗科技股份有限公司（以下简称"公司"）回购专用证券账户 中的股份 727,680 股不参与本次权益分派。公司 2024 年度利润分配方案为：以公司现 有总股本 8,960 万股扣减不参与利润分配的回购专用证券账户的股份 727,680 股，即 88,872,320 股为基数，向全体股东每 10 股派发现金股利人民币 4 元（含税），不送红 股，不以资本公积金转增股本。共计分配现金股利 35,548,928.00 元（含税）。 2、本次权益分派实施后，按公司总股本 89,600,000 股折算的每 10 股现金分红金 额以及据此计算的除权除息参考价的相关参数和公式计算如下： 按公司总股本（含回购股份）折算的每 10 股现金分红金额（含税）=本次实际现金 分红总额/公司总股本*10 股=35,548,928/89,600,000*10=3.967514 ...

证券代码：301367 证券简称：怡和嘉业 公告编号：2025-043 北京怡和嘉业医疗科技股份有限公司 关于变更公司名称、证券简称暨完成工商变更登记的公 告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 重要提示： 1、北京怡和嘉业医疗科技股份有限公司（以下简称"公司"）中文名称由"北京 怡和嘉业医疗科技股份有限公司"变更为"北京瑞迈特医疗科技股份有限公司"。 2、公司证券简称由"怡和嘉业"变更为"瑞迈特"，启用时间为 2025 年 5 月 21 日。 3、公司证券代码"301367"保持不变。 一、公司变更公司名称、证券简称的情况 2025 年 4 月 17 日，公司召开第三届董事会第十三次会议审议通过了《关于拟变更 公司名称、证券简称及修订<公司章程>的议案》，上述议案已经公司于 2025 年 5 月 13 日召开 2024 年年度股东大会审议通过，具体内容详见公司于 2025 年 4 月 18 日、2025 年 5 月 14 日于巨潮资讯网（http://www.cninfo.com.cn）披露的相关公告。 | | 变更前 | 变更后 | | --- ...

Group 1 - The core viewpoint of the news is that Panjing Investment has conducted research on a listed company, Yihe Jiaye, which is expected to see revenue and net profit growth in Q1 2025 due to the end of inventory destocking in the US ventilator market and the joining of a senior consumer goods marketing expert [1] - Yihe Jiaye's domestic market revenue and gross margin have improved, and the company has achieved basic localization of core components, ensuring supply chain security [1] - The company has established a strategic partnership with Hanyu Pharmaceutical to jointly develop projects combining ventilators and casein active peptides, expanding into health consumer goods channels [1] Group 2 - Yihe Jiaye has completed the construction of its cloud platform in the European market, connecting with over 20 agents [1] - The company has signed a confidentiality agreement with Qiangnao Technology to discuss advancing brain-computer interface technology cooperation [1] - The newly launched P5 series ventilators are primarily targeted at domestic hospital channels and have generated sales revenue in Q1 2025 [1]

Company Overview - Beijing Yihe Jiaye Medical Technology Co., Ltd. was established in 2001 and successfully listed on the Shenzhen Stock Exchange's Growth Enterprise Market on November 1, 2022 [1] - The company specializes in providing comprehensive treatment solutions for OSA and COPD patients, covering diagnosis, treatment, and chronic disease management [1] - It is a leading domestic enterprise in non-invasive ventilators and masks, with products sold in over 100 countries and regions [1] Research and Development - As of December 31, 2024, the company holds 633 valid patents in China, including 107 invention patents, 390 utility model patents, and 136 design patents [2] - The company has 202 valid overseas patents, including 39 in the United States and 30 in Europe [2] Financial Performance - In Q1 2025, the company reported growth in both revenue and net profit, attributed to the stabilization of the U.S. ventilator market and effective domestic channel policy adjustments [3] - Domestic business revenue and gross margin improved in Q1 2025, indicating a stable and positive trend in the domestic market [4] Supply Chain and Strategic Partnerships - The company has achieved significant localization in its supply chain, ensuring safety and cost advantages [5] - A strategic partnership with Shenzhen Hanyu Pharmaceutical Co., Ltd. aims to develop products for health consumer channels, targeting mild sleep disorder populations [6] Market Expansion - The company has completed the cloud platform construction for the European market, with over 20 agents connected, laying the groundwork for future growth in the mainstream medical insurance market [7] - The newly launched P5 series ventilators primarily target domestic hospital channels, contributing positively to future revenue and gross margin [8]

证券代码：301367 证券简称：怡和嘉业 公告编号：2025-041 特别提示： 1. 本次股东大会未出现否决议案的情形； 2. 本次股东大会未涉及变更前次股东大会已通过的决议的情形。 一、会议召开和出席情况 （一）会议召开情况 北京怡和嘉业医疗科技股份有限公司 2024年年度股东大会决议公告 1、会议召开的日期、时间： 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 （1）现场会议时间：2025 年 5 月 13 日（星期二）下午 14:00； 3、会议地点：北京市丰台区丽泽路 16 号院 4 号楼北京汇亚大厦 17 层 10 号 4、会议的召集人：公司第三届董事会 5、会议的主持人：董事长庄志先生 6、会议召开的合法、合规性：本次股东大会的召开程序符合《公司法》 《证券法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司 1 规范运作》等法律、法规、深交所业务规则和《公司章程》的相关规定。 （二）会议出席情况 1、股东出席的总体情况： （2）网络投票时间：2025 年 5 月 13 日，其中通过深交所交易系统进行网 络投票的具体时间为：2 ...

北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于北京怡和嘉业医疗科技股份有限公司 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出 席并见证贵公司 2024 年年度股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》 （以下简称"《股东会规则》"）、《律师事务所从事证券法律业务管理办法》 （以下简称"《证券法律业务管理办法》"）、《律师事务所证券法律业务执业 规则（试行）》（以下简称"《证券法律业务执业规则》"）等相关法律、行政 法规、规章、规范性文件及《北京怡和嘉业医疗科技股份有限公司章程》（以下 简称"《公司章程》"）的规定，就本次会议的召集与召开程序、召集人资格、 出席会议人员资格、会议表决程序及表决结果等事宜，出具本法律意见书。 对本法律意见书的出具，本所律师特作如下声明： 1．本所律师仅就本次会议的召集与召开程序、召集人和出 ...

今日焦点中国中车：近期签订合计547.4亿元重大合同 中国中车公告称，公司及下属企业于近期（主要为2024年12月至2025年5月）签订了若干项重大合同， 合计金额约547.4亿元人民币。主要合同包括城市轨道车辆、设备销售及维保合同，动车组销售合同， 动车组高级修合同，风电设备销售合同和储能设备销售合同，机车销售合同以及货车修理合同。上述合 同总金额约占公司中国会计准则下2024年营业收入的22.2%。 阳光诺和：拟购买朗研生命100%股权，股票明日复牌 南方财经5月12日电，阳光诺和(688621.SH)公告称，公司拟通过发行股份及可转换公司债券购买资产并 募集配套资金，购买利虔、朗颐投资等38名朗研生命股东持有的朗研生命100%股权。并向不超过35名 特定投资者发行股份募集配套资金。朗研生命专注于高端化学药及原料药的研发、生产和销售，并对外 提供药品生产服务，在高端化学药、原料药等领域深耕多年，已经形成了较为成熟的医药生产体系。公 司股票将于5月13日开市起复牌。 沃尔核材：筹划发行H股股票并申请在香港联交所主板上市 沃尔核材公告称，公司拟发行H股股票并申请在香港联交所主板挂牌上市，以推进国际化战略，提升 ...